Evaluating effects of tyrosine phosphatase inhibitors on T cell receptor signaling

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Tyrosine phosphorylation is vital for cell function, with dysregulation of protein tyrosine kinases (PTKs) and phosphatases (PTPs) linked to human diseases.
• Hematopoietic cells have numerous PTKs and PTPs; their malfunction contributes to hematopoietic disorders.
• While PTK inhibitors are established cancer therapies, PTP inhibitor development for therapeutic use is nascent.

Purpose of the Study:

• To describe methods for evaluating protein tyrosine phosphatase (PTP) inhibitor effects on T cell receptor signaling.
• To present a comprehensive strategy for compound prioritization in T cell-focused drug discovery.
• To provide detailed protocols and tips for working with primary human T cells and the Jurkat T cell line.

Main Methods:

• A tiered testing approach was employed, starting with luciferase reporter assays.
• Subsequent assays included immunoblot, calcium flux, flow cytometry, proliferation assays, cytokine bead arrays, and RNA interference for specificity.
• Protocols were developed for both the Jurkat T cell line and primary human T cells.

Main Results:

• The study details a functional testing funnel for assessing PTP inhibitor efficacy and specificity.
• It provides practical guidance for experimental execution, particularly with primary human T cells.
• The described strategy facilitates compound prioritization for drug discovery targeting T cell signaling pathways.

Conclusions:

• Effective methods for evaluating PTP inhibitors in T cell signaling are presented.
• A robust compound prioritization strategy is outlined for T cell drug discovery.
• The provided protocols enhance the ability to study PTPs in both cell lines and primary human T cells.